FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 329:723-725 September 2, 1993 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Acute myocardial infarction is the most common cause of death in most Western countries. The clinical description of acute myocardial infarction by Herrick¹ in 1912 suggested that acute coronary thrombosis was responsible. Indeed, the possibility of lysing occlusive thrombi in the coronary arteries was the principal rationale for the first trial of thrombolytic therapy with streptokinase in 1959². In the 1960s and 1970s, several randomized studies of intravenous thrombolytic therapy were conducted. However, widely varied treatment protocols and end-point analyses, along with small samples, produced conflicting results³. Furthermore, during this time the pathogenetic role of coronary-artery thrombus was . . . [Full Text of this Article]

References

Related Letters:

Thrombolytic Therapy for Acute Myocardial Infarction: GUSTO Criticized
Friedman H. S., Chelluri L., Sirio C. A., Angus D. C., Ogunyankin K., Topol E. J., Califf R. M., Van de Werf F., Fuster V.
Extract | Full Text  
N Engl J Med 1994; 330:504-506, Feb 17, 1994. Correspondence

This article has been cited by other articles:

• Coulter, S. A., Cannon, C. P., Ault, K. A., Antman, E. M., Van de Werf, F., Adgey, A. A. J., Gibson, C. M., Giugliano, R. P., Mascelli, M. A., Scherer, J., Barnathan, E. S., Braunwald, E., Kleiman, N. S. (2000). High Levels of Platelet Inhibition With Abciximab Despite Heightened Platelet Activation and Aggregation During Thrombolysis for Acute Myocardial Infarction : Results From TIMI (Thrombolysis In Myocardial Infarction) 14. Circulation 101: 2690-2695 [Abstract] [Full Text]  
• Chamuleau, S A J, de Winter, R J, Levi, M, Adams, R, Büller, H R, Prins, M H, Lie, K I, Peters, R J G (1998). Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction: the FATIMA study. Heart 80: 35-39 [Abstract] [Full Text]  
• Ridker, P. M., Hennekens, C. H. (1996). Age and Thrombolytic Therapy. Circulation 94: 1807-1808 [Full Text]  
• White, H. D., Barbash, G. I., Califf, R. M., Simes, R. J., Granger, C. B., Weaver, W. D., Kleiman, N. S., Aylward, P. E., Gore, J. M., Vahanian, A., Lee, K. L., Ross, A. M., Topol, E. J. (1996). Age and Outcome With Contemporary Thrombolytic Therapy: Results From the GUSTO-I Trial. Circulation 94: 1826-1833 [Abstract] [Full Text]  
• Friedman, H. S., Chelluri, L., Sirio, C. A., Angus, D. C., Ogunyankin, K., Topol, E. J., Califf, R. M., Van de Werf, F., Fuster, V. (1994). Thrombolytic Therapy for Acute Myocardial Infarction: GUSTO Criticized. NEJM 330: 504-506 [Full Text]  
• (1993). ACCELERATED t-PA VS. STREPTOKINASE FOR MI. JWatch General 1993: 1-1 [Full Text]